Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity

Qibin Leng, Marion Tarbe, Qi Long, Feng WangClinical 2020 · DOI

TL;DR

This review proposes that pre-existing T-cell immunity, acquired from exposure to microbes and vaccines, significantly influences how effectively the immune system recognizes and attacks tumor neoantigens. Understanding this "heterologous immunity" is crucial for developing more effective personalized cancer immunotherapies.

What Problem Does This Paper Address?

Cancer immunotherapies, particularly those targeting tumor-specific neoantigens, hold immense promise. Neoantigens are ideal targets because they are foreign to the immune system and can elicit strong T-cell responses, unlike overexpressed self-proteins that are often ignored due to central tolerance. However, predicting which neoantigens will actually trigger a robust anti-tumor immune response remains a major challenge. The authors highlight that current prediction algorithms, primarily based on HLA binding, are insufficient. They propose that a critical, yet underappreciated, factor influencing neoantigen immunogenicity is the host's prior exposure to a vast array of microbes and vaccines throughout their life. This pre-existing "heterologous immunity" can prime T-cells, potentially altering their response to novel tumor neoantigens through molecular mimicry.

Methods

This paper is a review, not an experimental study. Therefore, it doesn't present novel methods or algorithms. Instead, it synthesizes existing research and proposes a hypothesis. The authors draw upon findings from various studies that utilize:

  • In silico neoantigen prediction algorithms: These are standard computational tools used to identify potential neoantigens based on mutations in tumor DNA and HLA binding predictions.
  • Mass spectrometry data: Used to improve the prediction of neoantigens presented by HLA class II alleles.
  • Exome sequencing: To identify missense mutations in patient tumor tissues.
  • Serological profiling: To assess human exposure to various viral pathogens.
  • T-cell repertoire analysis: Including TCR sequencing and functional gene expression analysis at the single-cell level, to understand T-cell specificity and cross-reactivity.
  • Animal models and clinical trials: To evaluate the efficacy of neoantigen vaccines and the role of the gut microbiota in cancer immunotherapy.

Datasets

Not discussed in the paper. The paper reviews existing literature and does not introduce new datasets or benchmarks.

Key Insights and Ideas

  • Molecular Mimicry is Key: Tumor neoantigens can share structural similarities with antigens from common microbes (bacteria, viruses) or even self-antigens. This molecular mimicry is the basis for cross-reactivity between T-cells that have encountered microbial antigens and those that encounter neoantigens.
  • Pre-existing Memory Matters: Humans are constantly exposed to microbes and vaccines, leading to the generation of long-lived memory T-cells. These memory T-cells are primed to respond quickly and strongly to antigens they've encountered before, or antigens that resemble them.
  • Gut Microbiota as an "Immune Educator": The trillions of microbes in our gut play a significant role in shaping the immune system from birth. They can influence T-cell differentiation and function, and their antigens can prime T-cells that may later cross-react with tumor neoantigens.
  • Heterologous Immunity as an "Immune Editor": The immune system's history of encountering various pathogens can "edit" the T-cell repertoire. This edited repertoire then influences how the immune system perceives and responds to new challenges, including tumor neoantigens.
  • Beyond HLA Binding: Current neoantigen prediction relies heavily on HLA binding affinity. This review argues that this is insufficient and that factors like the T-cell repertoire, shaped by microbial exposure, are critical for determining true immunogenicity.

Key Results

This review doesn't present quantitative results in the traditional sense. Instead, it synthesizes evidence from various studies to support its central hypothesis:

  • Studies have identified specific neoantigens that share sequence homology with microbial peptides, suggesting potential cross-reactivity.
  • Evidence shows that memory T-cells can respond to previously unencountered antigens, and that prior exposure to one pathogen can alter the response to a subsequent, unrelated pathogen (heterologous immunity).
  • The gut microbiota has been shown to influence the efficacy of cancer immunotherapies, suggesting a link between microbial exposure and anti-tumor immunity.
  • A composite neoantigen quality model, incorporating sequence homology with pathogenic antigens, has shown promise in predicting patient survival.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • Under-investigated Area: The precise mechanisms by which pre-existing heterologous immunity affects neoantigen-specific T-cell responses are not yet fully understood.
  • Complexity of Microbial Influence: While the gut microbiota is implicated, the specific roles of different microbial genera (e.g., pro-inflammatory vs. tolerogenic) and how they influence neoantigen immunogenicity require further investigation.
  • Individual Variation: Human microbial exposure histories vary significantly, leading to diverse T-cell repertoires. Future research needs to account for this individual variability when predicting neoantigen immunogenicity.
  • TCR Repertoire Analysis: Advanced methods for TCR sequencing and functional gene expression analysis are needed to fully elucidate the mechanisms of heterologous immunity and its impact on neoantigen recognition.
  • Predictive Algorithms: Future algorithms for neoantigen prediction should incorporate factors beyond HLA binding, such as microbial exposure history and T-cell repertoire characteristics, to improve accuracy.
  • Pathogenic vs. Commensal Microbes: It remains to be investigated whether neoantigens cross-reactive to pathogenic microbes are more immunogenic than those cross-reactive to tolerant commensal microbes.

Summary updated

Abstract

Neoantigens are tumor-specific mutated proteins that are exempt from central tolerance and are therefore capable of efficiently eliciting effective T-cell responses. The identification of immunogenic neoantigens in tumor-specific mutated proteins has promising clinical implications for cancer immunotherapy. However, the factors that may contribute to neoantigen immunogenicity are not yet fully understood. Through molecular mimicry of antigens arising during cancer progression, the gut microbiota and previously encountered pathogens potentially have profound impacts on T-cell responses to previously unencountered tumor neoantigens. Here, we review the characteristics of immunogenic neoantigens and how host exposure to microbes may affect T-cell responses to neoantigens. We address the hypothesis that pre-existing heterologous memory T-cell immunity is a major factor that influences neoantigen immunogenicity in individual cancer patients. Accumulating data suggest that differences in individual histories of microbial exposure should be taken into account during the optimisation of algorithms that predict neoantigen immunogenicity.
BibTeX
@inproceedings{leng2020preexisting,
  author = {Qibin Leng and Marion Tarbe and Qi Long and Feng Wang},
  title = {{Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity}},
  booktitle = {Clinical},
  year = {2020},
  doi = {10.1002/cti2.1111},
}
Figure